Literature DB >> 12802030

Aromatase inhibitors in breast cancer.

Ian E Smith1, Mitch Dowsett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12802030     DOI： 10.1056/NEJMra023246

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  212 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Improving clinical research.

Authors:  Paul M Stewart
Journal:  BMJ       Date:  2003-11-01

Review 3.  Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.

Authors:  Shannon Puhalla; Saveri Bhattacharya; Nancy E Davidson
Journal:  Mol Oncol       Date:  2012-02-24       Impact factor: 6.603

4.  Optimal timing of adjuvant treatment in patients with early breast cancer.

Authors:  Necati Alkis; Ayse G Durnali; Ulku Y Arslan; Murat Kocer; Fatih O Onder; Saadet Tokluoglu; Gokhan Celenkoglu; Sadik Muallaoglu; Gungor Utkan; Arife Ulas; Kadri Altundag
Journal:  Med Oncol       Date:  2010-05-15       Impact factor: 3.064

Review 5.  Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.

Authors:  Debashis Ghosh; Jessica Lo; Chinaza Egbuta
Journal:  J Med Chem       Date:  2016-01-19       Impact factor: 7.446

6.  Mutated Pathways as a Guide to Adjuvant Therapy Treatments for Breast Cancer.

Authors:  Yang Liu; Zhenjun Hu; Charles DeLisi
Journal:  Mol Cancer Ther       Date:  2015-12-01       Impact factor: 6.261

7.  Targeting progesterone signaling prevents metastatic ovarian cancer.

Authors:  Olga Kim; Eun Young Park; Sun Young Kwon; Sojin Shin; Robert E Emerson; Yong-Hyun Shin; Francesco J DeMayo; John P Lydon; Donna M Coffey; Shannon M Hawkins; Lawrence A Quilliam; Dong-Joo Cheon; Facundo M Fernández; Kenneth P Nephew; Adam R Karpf; Martin Widschwendter; Anil K Sood; Robert C Bast; Andrew K Godwin; Kathy D Miller; Chi-Heum Cho; Jaeyeon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

8.  Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.

Authors:  R Rizzoli; J J Body; A DeCensi; A De Censi; J Y Reginster; P Piscitelli; M L Brandi
Journal:  Osteoporos Int       Date:  2012-01-20       Impact factor: 4.507

9.  Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.

Authors:  Young-Hyuck Im; Bulent Karabulut; Keun Seok Lee; Byeong-Woo Park; Aditya Adhav; Havva Yesil Cinkir; Hikmat Abdel-Razeq; Yuan-Ching Chang; Sercan Aksoy; Seock-Ah Im; Joon Jeong; Yeesoo Chae; James Bowles; Khemaies Slimane; Hongling Xue; Sung-Bae Kim
Journal:  Breast Cancer Res Treat       Date:  2021-03-16       Impact factor: 4.872

10.  Luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer.

Authors:  Kimihiro Tanaka; Eriko Tokunaga; Nami Yamashita; Kenji Taketani; Sayuri Akiyoshi; Masaru Morita; Yoshihiko Maehara
Journal:  Surg Today       Date:  2013-11-12       Impact factor: 2.549
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.